Related Experiment Videos
Modulation of fluorouracil toxicity with uridine
C J van Groeningen1, G J Peters, H M Pinedo
1Department of Oncology, Free University Hospital, Amsterdam, The Netherlands.
Seminars in Oncology
|April 1, 1992
Summary
Combining 5-fluorouracil (5-FU) with uridine may improve cancer treatment. Uridine could reduce 5-FU toxicity while maintaining its antitumor effects, but more research is needed for clinical use.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- 5-fluorouracil (5-FU) is a key antineoplastic agent with limited efficacy and complex metabolism.
- Biochemical modulating agents can enhance 5-FU's therapeutic index by interfering with its metabolism.
Purpose of the Study:
- To investigate the potential of uridine as a biochemical modulating agent to enhance 5-FU's therapeutic index.
- To assess the feasibility, toxicity, and pharmacokinetic profile of high-dose uridine in combination with 5-FU.
Main Methods:
- Preclinical studies in animal models demonstrated the activity of the 5-FU/uridine combination.
- Clinical studies focused on evaluating the tolerance and toxicity of high-dose uridine administered via intermittent intravenous infusions.
- Pharmacokinetic analysis was performed to determine plasma concentrations and half-life of uridine.
Main Results:
- High-dose uridine administration was feasible and reversed 5-FU-induced leukopenia in clinical studies.
- Uridine achieved millimolar plasma concentrations but had a short half-life due to rapid catabolism.
- Oral uridine administration showed low bioavailability.
Conclusions:
- High-dose uridine shows promise in modulating 5-FU toxicity and potentially enhancing its antitumor activity.
- Further research is necessary to optimize uridine delivery and overcome pharmacokinetic limitations for effective clinical application.
- The role of uridine in biochemical modulation of 5-FU requires further definition to establish its clinical utility.